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ASBTRACT 
Vaccination is a useful tool for the contrai of avian influenza (AI) outbreaks, but its use 
is forbidden in most countries worldwide because of its interference with AI screening 
tests and its negative impact on poultry trade. Currently licensed AI vaccines increase 
host resistance to the disease but have a limited impact on the virus transmission. To 
contrai or eradicate the disease, a carefully conceived vaccination strategy must be 
accompanied by strict bio-security measures. Sorne countries have, in the past, 
authorised vaccination under special circumstances with contrasting results, from 
contrai and disease eradication (USA, Italy) to endemism and antigenic drift of the viral 
strain (Mexico, Pakistan). Extensive vaccination pragrams are ongoing in Vietnam 
People's Republic of China and Indonesia to control the H5N 1 epidemic. This paper 
pravide practical information on the available AI vaccines and associated diagnostic 
tests, the vaccination strategies applied in Asia and their impact on the disease 
epidemiology. 
INTRODUCTION 
The control and eradication of highJy pathogenic avian influenza (HP AI) 
have relied so far on stamping out of infected animais and biosecurity 
measures including quarantine, surveillance and hygiene. Strategies for 
the control of low pathogenic viruses (LP AI) have varied from no action 
to control with vaccination. However, AI vaccination is prohibited in 
most countries because of export bans on vaccinated animals . Recently 
the World Organisation for Animal Health (OIE) and the United Nation's 
Food and Agricultural Organisation (FAO) have recomrnended the use of 
vaccination against H5Nl HP AI virus in developing countries where 
mass culling of poultry is no longer acceptable for "ethical, ecological 
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and economic reasons" . However, AI vaccination has been empirical so 
far and rules that have been applied in Europe are obsolete in most of the 
developing countries where biosecurity standards and poultry raising 
systems are very different (Rushton, 2006). Mass vaccination against 
H5Nl HP AI is currently in use in China, Vietnam and Indonesia and to 
some extend in Egypt and Sudan. The aim of this presentation is to 
review practical issues on the AI vaccination campaigns which have been 
implemented to date in China and South East Asia. 
A VIAN INFLUENZA VACCINES 
An ideal veterinary vaccine should be safe, potent, thermostable, single 
dose, easy to administer and allows the differentiation between vaccinated 
and infected animais. Three different types of avian influenza vaccines 
against H5Nl virus are available on the market and in use in Asia: 
inactivated heterologous vaccines (H5N2; H5N9); recombinant inactivated 
homologous vaccines (reverse genetic (RG) H5Nl) and live recombinant 
vaccines (H5 fowlpox and Newcastle viruses vectors (NDv)) (Capua and 
Marangon, 2006; Swayne, 2003). None of the avian influenza vaccines 
listed above satisfy the "ideal vaccine" criteria. Ail are cold chain 
dependant, a great limitation for developing countries where electric supply 
and cooling systems are not homogeneously available. They need to be 
parenterally injected via needles, a limiting factor in terms of labour and 
time in the case of mass vaccination of million of poultry. For inactivated 
vaccines multiple doses are necessary to confer protection. Only live 
vaccines could induce protection after a single dose but their efficacy might 
be impaired in adults because of previous natural infection. Differences 
have also been observed between laboratory and field efficacy for 
inactivated vaccines; especially in areas were immunosuppression with 
other circulating diseases ( e.g. Gumboro disease) is happening. 
UPDATE ON VACCINATION CAMPAIGNS 
Hong Kong has been using European H5N2 and Chinese RGH5Nl 
inactivated vaccines for their mass vaccination program since 2002. 
Vaccination strategy and biosecurity measures have proven to be 
effective as no outbreak was reported from 2004 until now whereas a 
nurnber of outbreaks occurred in adjacent regions of mainland China, 
Thailand, and Vietnam. 
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Mainland China produces and uses billions of doses of inactivated and 
live vaccines (H5N2, RGH5Nl , fowlpox H5 and NDv H5) and experts to 
Vietnam and Indonesia. To date more than 5 billions of poultry have 
been vaccinated since 2004 which has probably helped limiting the 
occurrences of human cases. 
Industrial farms in Vietnam or Indonesia have to pay for their own 
vaccination and import their vaccines from Europe or America. Vietnam 
government has been using Chinese H5Nl and H5N2 vaccines for their 
national campaigns since 2005 . The disease has been controlled with the 
last human case in Dec 2005. New outbreaks in poultry have occurred 
since Dec 2006 but were rapidly contained. There is an incentive in 
Vietnam to set up a local vaccine production as it is already the case in 
Indonesia. One of the main issues in vaccine production is the capacity to 
assess the protective efficacy of the vaccines both in the laboratory and in 
the field prior to general use. 
In Indonesia locally produced vaccines have been used for their national 
campaigns since 2005. Vaccine supply shortages along with specific 
practical issues for implementation of the campaigns have resulted in a 
limited coverage so far. The disease is still spreading along the islands 
and human cases are being accounted for each month. 
VACCINATION STRATEGIES 
AI vaccines increase host resistance to AI disease and reduce viral 
excretion therefore reducing the risk of contact infection within flocks (van 
der Goot et al., 2005). However, protection is species dependant and varies 
also with the degree of homology between the vaccine strain and the 
circulating virus. Vaccination is only a tool and should be used along with 
the improvement of biosecurity measures. China, Vietnam and Indonesia 
are all applying mass vaccination programs with some specificity but they 
are ail facing issues specific to developing countries: 
- rational behind the choice of vaccine according to its homology with the 
circulating virus and efficacy in the targeted species (Webster et al., 2006); 
- post-vaccination surveillance to assess 1) the efficacy of vaccination and 
2) monitor the antigenic drift of the field virus (Lee et al. , 2004). Lack of 
resources and organisational tools are limiting the application of efficient 
post-vaccination monitoring programs in most developing countries; 
- information program on advantages and limitations of avian influenza 
vaccination: even in remote areas, farmers needs to be aware that 
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vaccination do not prevent infection and that multiple doses are required 
to confer immunity; 
- choice of vaccination protocols: countries are facing practical and 
financial difficulties to implement mass vaccination ( discrepancy 
between provincial strategies; low vaccination coverage; unavailability of 
vaccines) . The sustainability of such vaccination strategy on a long term 
needs to be addressed (cost-benefit analysis); 
- economic impacts: cost-effectiveness of different control strategies must 
be evaluated. 
DISCUSSION 
To effectively control the virus from circulating in poultry, an efficient 
post-vaccination surveillance program should be established. This appears 
to be the main challenge for developing countries along with the 
economical issues. A performing control and eradication programme 
should also include strict quarantines, movement controls on animais and 
equipment, strengtbened biosecurity, extensive surveillance, and a 
comprehensive education programme for the public. 
More research on vaccines optimisation is needed. To date, AI vaccines 
have not been used extensively and companies have not felt the need to 
focus research irnproving such vaccines. Even though numerous 
experirnental AI vaccines are under development, basic data on efficacy of 
currently used vaccines are still lacking. Eradication of the disease within a 
poultry population will not be achieved if effective vaccines are not 
available for waterfowl. 
New concems recently have arisen regarding the illegal use of vaccines 
obtained from "underground" or "black" markets. The illegal use of AI 
vaccines bas been reported in some countries where vaccination against AI 
is still prohibited. A thorough control and communication program on the 
benefits and limits of AI vaccination needs to be developed quickly and put 
in place. 
AI vaccine markets are expanding. More developing countries are planning 
to produce their own vaccine to meet domestic need. However, it is difficult 
for a small country to compete with international pharmaceutical 
companies in the AI vaccine markets. Moreover they might be lacking the 
resources to set up "Quality control'' and potency assessment of the 
vaccmes. 
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CONCLUSION 
Through the Asian experience, it bas become clear that AI vaccination is 
already playing an essential part in the control of the actual H5Nl 
panzootic in developing countries. And its use will be quickly spreading to 
recently infected African countries. However, a case per case analysis 
should be performed in the decision making process to implement 
vaccination or not. New set of tools (risk modelling, economical models ... ) 
are required to help this decision making along with further research in the 
optimisation of avian influenza vaccines. There is also a great need to 
improve veterinary policy and capacity of veterinary services for a better 
control. Uncontrolled vaccination, including the improper distribution and 
administration of a vaccine and/or the use of bad vaccines, poses a greater 
threat in further outbreaks, which raises the possibility of potential mutation 
of the virus to become a pandernic pathogen. 
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